The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome: A Randomized Trial
Abstract
BACKGROUND: Alterations in gut flora may be important in the pathophysiology of the irritable bowel syndrome (IBS). OBJECTIVE: To determine whether the nonabsorbed antibiotic rifaximin is more effective than placebo in reducing symptoms in adults with IBS. DESIGN: Double-blind, randomized, placebo-controlled study. SETTING: 2 tertiary care medical centers. PARTICIPANTS: 87 patients who met Rome I criteria for IBS and were enrolled from December 2003 to March 2005. INTERVENTIONS: Participants who met enrollment criteria were randomly assigned to receive 400 mg of rifaximin 3 times daily for 10 days (n = 43) or placebo (n = 44). Eighty participants completed rifaximin therapy or placebo, and follow-up data were available for at least 34 participants per study group at any time point thereafter. MEASUREMENTS: A questionnaire was administered before treatment and 7 days after treatment. The primary outcome was global improvement in IBS. Patients were then asked to keep a weekly symptom diary for 10 weeks. RESULTS: Over the 10 weeks of follow-up, rifaximin resulted in greater improvement in IBS symptoms (P = 0.020). In addition, rifaximin recipients had a lower bloating score after treatment. LIMITATIONS: The major limitations of the study were its modest sample size and short duration and that most patients were from 1 center. CONCLUSIONS: Rifaximin improves IBS symptoms for up to 10 weeks after the discontinuation of therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are three fully-published, double blind, placebo controlled trials of rifaximin in FBD187–189 and the data suggest an improvement in symptoms, especially bloating and flatulence for approximately 10 weeks following treatment187 189 with a therapeutic advantage over placebo around 10%.”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [187]
In the citing paper
“A short course of a non-absorbable antibiotic such as rifaximin has been shown to moderately improve the symptoms of irritable bowel syndrome (IBS), particularly bloating and flatulence.”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [187]
In the citing paper
“Improvement persists after the cessation of treatment but the exact duration of this effect remains uncertain.”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [187]
In the citing paper
“Other studies have demonstrated beneficial effect of antibiotics in patients with IBS regardless of either the diagnosis of SIBO or the effect of antibiotics on HBT (95, 100, 114, 134, 137–139, 160).”
From Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome (2013) · cites this paper as [139]
Citations
Cites
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448
Hungin, A. P. S., Whorwell, P. J., Tack, J., & Mearin, F. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01456.x · Cited by 781
Eradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome
Pimentel, M., Chow, E. J., & Lin, H. C. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03368.x · Cited by 780
Self-citationAgréus, L., Svärdsudd, K., Nyrén, O., & Tibblin, G. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90373-9 · Cited by 686
Pimentel, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05902-6 · Cited by 669
Self-citationDesign of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
Drossman, D. A. (1994) · Medical Entomology and Zoology · Cited by 470
Müller‐Lissner, S. A., Fumagalli, I., Bardhan, K. D., Pace, F., Pecher, E., Nault, B., & Rüegg, P. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.01094.x · Cited by 463
Camilleri, Mayer, Drossman, Heath, Dukes, Mcsorley, Kong, Mangel, & Northcutt (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00610.x · Cited by 369
Research works printed but not linked: 6
- Wilson S, 2004, Br J Gen Pract, 54, 495
- El-Serag HB, 2003, Rev Gastroenterol Disord, 3, S3
- Pimentel M, 2003, Am J Gastroenterol, 98, 412
- Veldhuyzen van Zanten SJ, 1999, Gut, 45, II69
- Balsari A, 1982, Microbiologica, 5, 185
- Cuoco L, 2006, Minerva Gastroenterol Dietol, 52, 89
Cited by
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Self-citationPostinfectious Irritable Bowel Syndrome
Spiller, R., & Garsed, K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.074 · Cited by 1,024
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939
Guidelines on the irritable bowel syndrome: mechanisms and practical management
Spiller, R., Aziz, Q., Creed, F., Emmanuel, A., Houghton, L., Hungin, P., Jones, R., Kumar, D., Rubin, G., Trudgill, N., et al. (2007) · Gut · doi:10.1136/gut.2007.119446 · Cited by 818
Diverticular Disease of the Colon
Fox, J. M., & Stollman, N. H. (2010) · Sleisenger and Fordtran's Gastrointestinal and Liver Disease · doi:10.1016/b978-1-4160-6189-2.00117-7 · Cited by 820
Metadata
- Authors
- Pimentel, M., Park, S., Mirocha, J., Kane, S. V., & Kong, Y.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2006-10-17
- Volume
- 145
- Issue
- 8
- Pages
- 557-563
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2103771013
- Cited by
- 466
- References
- 28
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 3 · 2023: 10 · 2022: 8 · 2021: 14 · 2020: 12 · 2019: 13 · 2018: 23 · 2017: 20 · 2016: 23 · 2015: 26 · 2014: 26 · 2013: 21 · 2012: 33
- FWCI
- 34.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- irritable bowel syndrome, rifaximin, gut microbiota, IBS symptoms, bloating, symptom improvement, placebo comparison
- MeSH terms
- Rifaximin, Adolescent, Adult, Aged, Anti-Infective Agents, Blind Loop Syndrome, Double-Blind Method, Female, Follow-Up Studies, Gastrointestinal Agents, Humans, Male, Middle Aged, Rifamycins, Treatment Outcome, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome: A Randomized Trial. https://app.cochat.ai/papers/10.7326/0003-4819-145-8-200610170-00004
- The paper
- Pimentel, M., Park, S., Mirocha, J., Kane, S. V., & Kong, Y. (2006). The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome: A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-145-8-200610170-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.